Salvaris R, Allanson B, Collins G, Cheah C
Haematologica. 2024; 109(11):3476-3487.
PMID: 39234861
PMC: 11532684.
DOI: 10.3324/haematol.2024.285903.
Kumbhalwar K, Punatar S, Gokarn A, Nayak L, Chichra A, Mirgh S
Blood Cell Ther. 2023; 6(3):95-103.
PMID: 38146353
PMC: 10749212.
DOI: 10.31547/bct-2023-009.
Fehniger T, Watkins M, Ezenwajiaku N, Wan F, Hurd D, Cashen A
Haematologica. 2023; 109(3):953-957.
PMID: 37706336
PMC: 10905073.
DOI: 10.3324/haematol.2022.282246.
Mehta-Shah N, Lunning M, Moskowitz A, Boruchov A, Ruan J, Lynch P
Am J Hematol. 2021; 96(10):1211-1222.
PMID: 34251048
PMC: 8811706.
DOI: 10.1002/ajh.26288.
Ma H, Cheng B, Montanari F, Lue J, Deng C, Marchi E
Ther Adv Hematol. 2020; 11:2040620720947340.
PMID: 33062232
PMC: 7534065.
DOI: 10.1177/2040620720947340.
Moving things forward in Hodgkin lymphoma.
Brockelmann P, Boll B
F1000Res. 2018; 7.
PMID: 30473768
PMC: 6234718.
DOI: 10.12688/f1000research.16077.1.
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma.
Garcia-Recio M, Martinez-Serra J, Mestre F, Bento L, Gines J, Ramos R
Onco Targets Ther. 2018; 11:6599-6603.
PMID: 30349293
PMC: 6188182.
DOI: 10.2147/OTT.S175016.
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience.
Rocha T, Fortier S, Fischer T, Perini G, Gaiolla R, Fogliatto L
Rev Bras Hematol Hemoter. 2017; 39(3):216-222.
PMID: 28830600
PMC: 5567422.
DOI: 10.1016/j.bjhh.2017.03.008.
New agents in relapsed/refractory Hodgkin's lymphoma.
Biasoli I, Spector N
Rev Bras Hematol Hemoter. 2017; 39(3):193-196.
PMID: 28830595
PMC: 5568577.
DOI: 10.1016/j.bjhh.2017.05.003.
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Maly J, Christian B, Zhu X, Wei L, Sexton J, Jaglowski S
Clin Lymphoma Myeloma Leuk. 2017; 17(6):347-353.
PMID: 28622959
PMC: 6033275.
DOI: 10.1016/j.clml.2017.05.008.
Outcome of 1051 Octogenarian Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Observational Cohort From the London Heart Attack Group.
Bromage D, Jones D, Rathod K, Grout C, Iqbal M, Lim P
J Am Heart Assoc. 2016; 5(6).
PMID: 27353606
PMC: 4937253.
DOI: 10.1161/JAHA.115.003027.
Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.
Gharbaran R
Tumour Biol. 2016; 37(9):11573-11588.
PMID: 27317256
DOI: 10.1007/s13277-016-5118-7.
Trial Watch: Lenalidomide-based immunochemotherapy.
Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G
Oncoimmunology. 2014; 2(11):e26494.
PMID: 24482747
PMC: 3897503.
DOI: 10.4161/onci.26494.
Thalidomide-a notorious sedative to a wonder anticancer drug.
Zhou S, Wang F, Hsieh T, Wu J, Wu E
Curr Med Chem. 2013; 20(33):4102-8.
PMID: 23931282
PMC: 4112512.
DOI: 10.2174/09298673113209990198.
Novel therapies for Hodgkin Lymphoma.
Sweetenham J
Ther Adv Hematol. 2013; 1(1):23-9.
PMID: 23556069
PMC: 3573386.
DOI: 10.1177/2040620710387980.
Advances in the treatment of Hodgkin lymphoma.
Eichenauer D, Engert A
Int J Hematol. 2012; 96(5):535-43.
PMID: 23054655
DOI: 10.1007/s12185-012-1199-2.
Hodgkin lymphoma.
Kuppers R, Engert A, Hansmann M
J Clin Invest. 2012; 122(10):3439-47.
PMID: 23023715
PMC: 3534167.
DOI: 10.1172/JCI61245.
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.
de la Cruz-Merino L, Lejeune M, Nogales Fernandez E, Henao Carrasco F, Grueso Lopez A, Illescas Vacas A
Clin Dev Immunol. 2012; 2012:756353.
PMID: 22927872
PMC: 3426211.
DOI: 10.1155/2012/756353.
Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.
Kowalska M, Tajer J, Chechlinska M, Fuksiewicz M, Kotowicz B, Syczewska M
Tumour Biol. 2012; 33(5):1733-8.
PMID: 22678978
DOI: 10.1007/s13277-012-0432-1.
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Ramchandren R
Oncologist. 2012; 17(3):367-76.
PMID: 22387318
PMC: 3316922.
DOI: 10.1634/theoncologist.2011-0258.
